The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.
January
21 SRT systems shipped during the quarter; revenues of $8.3…
January
Keloid recurrence rate of 10.4% at 12 months for patients…
January
Recently, a study was conducted on the efficacy of the…
January
Recently, Sensus Healthcare’s CEO, Joe Sardano, was featured on a…
January
What Are the Types of Non-Melanoma Skin Cancer? First, for…
